Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.4.1 (
phosphodiesterase
)
18,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Insulin
action is thought to be mediated by an inositol-, glucosamine- and galactose-containing oligosaccharide liberated by
phosphodiesterase
hydrolysis of a glycosyl-phosphatidylinositol. This oligosaccharide inhibits
insulin
biosynthesis and secretion in pancreatic islets. In the present study, two main glycolipids (peak I and II) were resolved by sequential TLC of lipids extracted from islet cells labelled with tritiated glucosamine, galactose or myristate. The two glycolipids displayed comparable sensitivity to beta-galactosidase but differed from one another by their sensitivity to phosphatidylinositol-specific phospholipase C. Moreover, structural heterogeneity within each peak was suggested by their partial resistance to nitrous acid deamination. These findings support the presence in islet cells of glycolipids similar to those currently considered as a possible postreceptor target for
insulin
in other cell types.
...
PMID:Metabolic labelling and partial characterization of glycophospholipids in pancreatic islet cells. 165 34
The involvement of cAMP- and calcium-dependent pathways on the inhibitory effect of CsA (0.5 micrograms/ml) on
insulin
and glucagon release was studied in collagenase-isolated islets. CsA suppressed by 50% the release of
insulin
in pertussis toxin treated islets stimulated by 20 mM D-glucose. CsA blocked glucagon and
insulin
release induced by 0.2 mM IBMX (80% and 50% respectively). Similarly it inhibited glucagon and
insulin
release induced by 1 microM A23187 (53% and 40% respectively). CsA also abolished 0.1 microM glucagon-induced
insulin
release and 10 ng/ml VIP-induced glucagon release (70% and 38% respectively). The glucagon response to 2 mM D-glucose and to 10 mM arginine was decreased 25% and 45% respectively by CsA. The inhibitory effect of 0.1 microM somatostatin on
insulin
release was significantly abolished by CsA (p less than 0.001 vs control). On the other hand 1 microM forskolin induced
insulin
and glucagon release was not modified by CsA. Rats treated with CsA (10 mg/kg body wt) during 10 days showed hyperglycaemia, hypoglucagonemia and higher contents of pancreatic glucagon. It is concluded that CsA affects alpha- and beta-cell function, in vivo and in vitro, acting through calcium and cAMP-dependent pathways. This latter pathway involves the Ca(2+)-calmodulin dependent
phosphodiesterase
and the regulatory proteins Gs and Gi.
...
PMID:Mechanisms of action of cyclosporin A on islet alpha- and beta-cells. Effects on cAMP- and calcium-dependent pathways. 166 May 57
Three
phosphodiesterase
(
PDE
) type III inhibitors were tested and found to inhibit Xenopus oocyte maturation induced by
insulin
with apparent IC50 values of 2.2 +/- 0.2 microM Cl-930, 25 +/- 3 microM imazodan (Cl-914), and 786 +/- 237 microM piroximone (MDL 19,205). The same rank order of potencies was observed for inhibition of insulin-like growth factor-I (IGF-I)-induced oocyte maturation, with IC50 values of 5.5 +/- 0.9 microM Cl-930, 54 +/- 4 microM imazodan, and 1190 +/- 395 microM piroximone. Oocyte maturation induced by microinjection of Ha p21ras was also inhibited by pretreatment of oocytes with Cl-930 or imazodan, with IC50 values of 4.3 +/- 1.2 and 59 +/- 4 microM, respectively. Progesterone-induced maturation was not affected by
PDE
III inhibitor action; and, neither type IV
PDE
inhibitors (Ro 20, 1724 or rolipram) nor dipyridamole (a type V
PDE
inhibitor) inhibited cell division induced by IGF-I or microinjected Ha p21ras. In addition, while
insulin
-stimulated oocyte
PDE
activity measured in vivo after microinjection of 200 microM [3H] cAMP was inhibited by nonselective and type III-specific drugs (with IC50 values of 4.2 +/- 1.8 microM Cl-930 and 26 +/- 6 microM imazodan), type IV and type V inhibitors did not inhibit hormone-stimulated enzyme activity. This pharmacological evidence demonstrates a necessary role for
PDE
III in
insulin
-, IGF-I-, and p21ras-induced meiotic cell division in Xenopus laevis oocytes.
...
PMID:Type III phosphodiesterase plays a necessary role in the growth-promoting actions of insulin, insulin-like growth factor-I, and Ha p21ras in Xenopus laevis oocytes. 166 4
Autophagy is a non-selective bulk process for degradation of cytoplasm, as indicated by ultrastructural evidence and by the similarity in autophagic sequestration rates of various cytosolic enzymes with different half-lifes. The initial autophagic sequestration step is subject to feedback inhibition by amino acids, an effect which is potentiated by
insulin
and antagonized by glucagon. Epinephrine and other adrenergic agonists inhibit autophagic sequestration through a prazosin-sensitive, alpha 1-adrenergic mechanism. The sequestration is also inhibited by cAMP and by protein phosphorylation as indicated by the effects of cyclic nucleotide analogues,
phosphodiesterase
inhibitors and okadaic acid. Asparagine specifically inhibits autophagic-lysosomal fusion without having any significant effects on autophagic sequestration, intralysosomal degradation or on the endocytic pathway. Autophaged material that accumulates in prelysosomal vacuoles in the presence of asparagine is accessible to endocytosed enzymes, revealing the existence of an amphifunctional organelle, the amphisome. Evidence from several cell types suggests that endocytosis may be coupled to autophagy in a differential (ligand-dependent) manner, and that amphisomes may play a central role as collecting stations for material destined for lysosomal degradation.
...
PMID:Hepatocytic autophagy. 166 81
The present studies demonstrate that the beta-cell line RINr1046-38 (RIN-38) retains the capability to secrete
insulin
in response to glucose. The maximal effect of glucose was a 5- to 9-fold stimulation of
insulin
secretion from RIN-38 cells. This glucose-induced
insulin
secretion was maximal at 0.6 mM and was modulated by other secretagogues. Potassium concentrations of 10 mM, adenylate cyclase activators (glucagon-like peptide-1 and forskolin), and a
phosphodiesterase
inhibitor (isobutylmethylxanthine) potentiated glucose-induced
insulin
secretion, but had little or no effect on
insulin
secretion in the absence of glucose. Potassium concentrations of 20 mM or more, glibenclamide, and carbachol (Cch) stimulated
insulin
secretion 8- to 12-fold in the absence of glucose, while only Cch potentiated the effect of glucose on
insulin
secretion. Amino acids (alanine, arginine, leucine, and ketoisocaproate) also stimulated
insulin
secretion. The alpha 2-adrenergic agonist clonidine (1 microM), low extracellular calcium (less than or equal to 0.5 mM), and extended culture of RIN-38 cells at low glucose concentrations (0.33 mM) inhibited the stimulatory effect of glucose on
insulin
secretion.
Insulin
secretion was retained in RIN-38 cells for up to 98 passages. However, extended passage was associated with a decline in cellular
insulin
content (83% decline over 89 passages). In addition, high passage cells lost the ability to secrete
insulin
in response to glucose, but continued to respond to other secretagogues (K+, alanine, and carbachol). In fact, in the absence of glucose the effect of Cch on
insulin
secretion was well maintained in high passage cells (8- and 9.9-fold increase in
insulin
secretion, passages 9 and 70, respectively). Thus, low passage RIN-38 cells secrete
insulin
in response to glucose and other
insulin
secretagogues. High passage cells do not respond to glucose, but continue to respond to other secretagogues. Based on these results we propose that high and low passage RIN-38 cells provide a model for examining molecular mechanisms of glucose-induced
insulin
secretion. In addition, these findings emphasize that passage information is essential for interpretation of secretion studies with RIN cell lines.
...
PMID:Modulation of glucose-induced insulin secretion from a rat clonal beta-cell line. 170 Nov 27
1. Phosphodiesterase activity in rat liver supernatant and solubilized rat liver particulate fractions was chromatographed on Q Sepharose and several characteristics of each peak determined. 2. Rat liver supernatant contained four peaks of activity. The first two of these corresponded to type I and II phosphodiesterases. The fourth peaks was similar to a type V activity and the third peak could not be definitely classified. 3. Particulate activity solubilized by mild protease treatment also contained four peaks of activity. The first two corresponded to the first two from the supernatant, the fourth was a type IV enzyme which is the
insulin
activated
phosphodiesterase
. The third peak could not be definitely characterized. 4. Particulate activity solubilised by Triton X-100 contained three peaks. Two had the properties of a type IV enzyme but only one of these was immunologically identified as the
insulin
sensitive enzyme. The remaining activity was similar to the chymotrypsin peak 3 activity. 5. Most of the particulate
phosphodiesterase
of rat liver is found in a microsomal fraction, and most is the
insulin
sensitive type IV enzyme.
...
PMID:Properties and distribution of cyclic AMP phosphodiesterase from rat liver. 170 19
A new cyclic AMP phosphodiesterase inhibitor, griseolic acid (CAS 79030-08-3), in a dose-dependent manner increased
insulin
release and cyclic AMP level in rat pancreatic islets in the presence of 5.5 mmol/l glucose. Griseolic acid (0.26 mmol/l) or 3-isobutyl-1-methylxanthine (IBMX) (1 mmol/l) enhanced
insulin
release and cyclic AMP level both in the presence of 5.5 and 16.7 mmol/l glucose (no significant difference). In perifusion system, 45Ca++ efflux and
insulin
release showed a monophasic increase when the islets were exposed to 1.3 mmol/l griseolic acid or 1 mmol/l IBMX in the presence of 5.5 mmol/l glucose (no significant difference). In a cell-free system, griseolic acid had a stronger inhibitory effect on cyclic AMP phosphodiesterase activity than IBMX, has a stimulatory effect on
insulin
release through an increase of cyclic AMP by inhibiting
phosphodiesterase
in pancreatic islets, but it might not cross the plasma membrane easily.
...
PMID:Effects of the new phosphodiesterase inhibitor griseolic acid on insulin release in rat pancreatic islets. 170 26
The effects of U-61,431F, ciprostene, a stable prostacyclin analogue, were examined on the proliferation of cultured quiescent bovine aortic endothelial cells (EC) and smooth muscle cells (SMC). After stimulation with 5% fetal calf serum, U-61,431F suppressed both the DNA synthesis and proliferation of SMC dose-dependently at the concentration of 3-100 microM, but had no effect on either of them in EC at a concentration of up to 30 microM. The inhibitory effect on DNA synthesis was greater in SMC than in EC at 3-50 microM. When SMC were stimulated with platelet-derived growth factor (PDGF) for 2 hrs followed by a 22-hr incubation with
insulin
, U-61,431F (1-50 microM) administered at the time of PDGF stimulation did not inhibit DNA synthesis. SMC initiated and terminated DNA synthesis at about 15-18 h and 24 h after stimulation with serum, respectively. Inhibition of DNA synthesis in serum-stimulated SMC as a function of the addition time of U-61,431F reduced at 3-12 h after the stimulation. U-61,431F raised the cyclic AMP (cAMP) content in SMC. Moreover, a
phosphodiesterase
inhibitor, 3-isobutyl-1-methylxanthine, and a more specific cAMP
phosphodiesterase
inhibitor, Ro 20-1724, augmented the inhibition of DNA synthesis in SMC concomitant with further elevation of cAMP level. These results suggest that U-61,431F inhibits DNA synthesis of SMC acting in the progression stage rather than in the competence stage, with little antiproliferative effect on EC. cAMP may play an important role in its antiproliferative action in SMC.
...
PMID:U-61,431F, a stable prostacyclin analogue, inhibits the proliferation of bovine vascular smooth muscle cells with little antiproliferative effect on endothelial cells. 170 56
Cyclic AMP phosphodiesterase in rat adipocytes is stimulated by
insulin
and also by agents that increase cyclic AMP levels. When the enzyme is immunoprecipitated from a solubilised microsomal preparation from adipocytes prelabelled with radioactive phosphate and separated on SDS polyacrylamide gels, label is found in a protein band at the expected Mr for adipose tissue
phosphodiesterase
. Treatment of the adipocytes with isoproterenol or methyl isobutylxanthine increased the labelling of this band.
Insulin
alone had no effect on its labelling but did decrease the incorporation of label caused by isoproterenol.
...
PMID:Phosphorylation of hormone sensitive phosphodiesterase in isolated adipocytes. 170 64
1. In rat isolated islets of Langerhans the selective beta 2-adrenoceptor agonist, clenbuterol (1 to 20 microM), significantly increased the level of adenosine 3':5'-cyclic monophosphate (cyclic AMP) within 2 min of incubation. 2. The cyclic AMP response to clenbuterol was inhibited in the presence of the selective beta 2 adrenoceptor antagonist, ICI 118551 (0.1 or 10 microM) but remained unchanged when the beta 1-antagonist, atenolol (0.1 microM) was administered. 3. Despite causing an elevation in cyclic AMP, clenbuterol (up to 20 microM) failed to influence
insulin
secretion at any glucose concentration tested, even in the presence of a
phosphodiesterase
inhibitor. 4. By contrast, clenbuterol elicited a dose-dependent rise in the rate of glucagon secretion; the maximal agonist-induced increase in secretion was two fold, a response equivalent to that observed with 20 mM L-arginine. 5. ICI 118551 significantly inhibited the rise in glucagon secretion induced by clenbuterol (up to 20 microM). 6. The results indicate that the rat islet A cell population is equipped with functional beta 2-adrenoceptors which influence glucagon secretion via the second messenger cyclic AMP, but that the B cells are deficient in functional beta-receptors.
...
PMID:Selective stimulation of glucagon secretion by beta 2-adrenoceptors in isolated islets of Langerhans of the rat. 171 26
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>